SEARCH

SEARCH BY CITATION

References

  • 1
    Nalesnik MA. Clinicopathologic features of posttransplant lymphoproliferative disorders. Ann Transplant 1997; 2: 3340.
  • 2
    Nalesnik MA. Posttransplantation lymphoproliferative disorders (PTLD): current perspectives. Semin Thorac Cardiovasc Surg 1996; 8: 139148.
  • 3
    Alfrey EJ, Friedman AL, Grossman RA et al. A recent decrease in the time to development of monomorphous and polymorphous posttransplant lymphoproliferative disorder. Transplantation 1992; 54: 250253.
  • 4
    Harmon WE, Dharnidharka VR. Lymphoproliferative disease in children. Transplant Proc 1999; 31: 12681269.
  • 5
    Leblond V, Sutton L, Dorent R et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995; 13: 961968.
  • 6
    Newell KA, Alonso EM, Whitington PF et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996; 62: 370375.
  • 7
    Walker RC, Paya CV, Marshall WF et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14: 214221.
  • 8
    Walker RC, Marshall WF, Strickler JG et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 13461353.
  • 9
    Manez R, Breinig MC, Linden P et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997; 176: 14621467.
  • 10
    Swinnen LJ, Costanzo-Nordin MR, Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 17231728.
  • 11
    Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation 1993; 56: 8896.
  • 12
    Cox KL, Lawrence-Miyasaki LS, Garcia-Kennedy R et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995; 59: 524529.
  • 13
    Sokal EM, Antunes H, Beguin C et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997; 64: 14381442.
  • 14
    Younes BS, McDiarmid SV, Martin MG et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 2000; 70: 9499.
  • 15
    Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE. Risk factors for post transplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation. A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 71: 10651068.
  • 16
    Alexander SR, Arbus GS, Butt KM et al. The 1989 report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1990; 4: 542553.
  • 17
    Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report – 2001. J Heart Lung Transplant 2001; 20: 805815.
  • 18
    SPLIT Research Group. Studies of Pediatric Liver Transplantation (SPLIT): year 2000 outcomes. Transplantation 2001; 72: 463476.
  • 19
    Hanto DW, Sakamoto K, Purtilo DT, Simmons RL, Najarian JS. The Epstein-Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Clinical, pathologic, and virologic correlation. Surgery 1981; 90: 204213.
  • 20
    Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; i: 583587.
  • 21
    Reyes J, Bueno J, Kocoshis S et al. Current status of intestinal transplantation in children. J Pediatr Surg 1998; 33: 243254.
  • 22
    Finn L, Reyes J, Bueno J et al. Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol 1998; 22: 299309.
  • 23
    Chen JM, Barr ML, Chadburn A et al. Management of lymphoproliferative disorders after cardiac transplantation. Ann Thorac Surg 1993; 56: 527538.
  • 24
    Ciancio G, Siquijor AP, Burke GW et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. Clin Transplant 1997; 11: 243249.
  • 25
    Mihalov ML, Gattuso P, Abraham K, Holmes EW, Reddy V. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Clin Transplant 1996; 10: 248255.
  • 26
    Badley AD, Portela DF, Patel R et al. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transpl Surg 1996; 2: 375382.
  • 27
    Darenkov IA, Marcarelli MA, Basadonna GP et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997; 64: 848852.
  • 28
    McDiarmid SV, Jordan S, Lee GS et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 16041611.